Manual acupuncture plus usual care versus usual care alone in the treatment of endometriosis-related chronic pelvic pain: study protocol for a randomised controlled feasibility study

Mike Armour1*, Caroline A. Smith1, Siobhan Schabrun2, Genevieve Z. Steiner1, Xiaoshu Zhu1, Kenny Lawson3 and Jing Song4

Abstract

Background: Endometriosis is the most common cause of chronic pelvic pain worldwide. Non-surgical treatments are effective for only 30–50% of women and have a significant side effect burden that leads to high discontinuation rates. Surgery can be effective but is expensive and invasive, and symptoms tend to recur within 5 years. There is early evidence that acupuncture may be effective in treating endometriosis-related chronic pelvic pain, showing clinically significant analgesia. Both levels of inflammation and pain processing have been shown to be altered in women with chronic pelvic pain. Acupuncture has been shown to reduce inflammation and change central pain processing in other conditions, but research on women with endometriosis is currently lacking. The aim of this feasibility study is to provide data on recruitment rates, retention, appropriateness of outcome measures, minimal clinically important difference in numeric rated scales for pain and the potential effect of acupuncture on pain processing and markers of inflammation in endometriosis-related CPP.

Methods: We will include women aged 18–45 years with a diagnosis of endometriosis via laparoscopy in the past 5 years. A total of 30 participants will be recruited and randomly allocated in a 1:1 ratio to receive acupuncture or usual care. Women in the acupuncture group will receive two 45-min treatment sessions per week for 8 weeks (total of 16 sessions). Women in the usual care group will continue with their current treatment regimen. The primary feasibility outcomes are recruitment rates, retention rates and the safety and acceptability of the intervention; secondary patient-centred outcomes include a change in 0–10 daily pelvic pain ratings, the Endometriosis Health Profile 30 (EHP-30) and changes in conditioned pain modulation, resting and task-related EEG activity and inflammatory markers. Analyses will be performed blind to group allocation.

Discussion: This is a two-armed, assessor blind, randomised controlled feasibility trial. Data will be compared at baseline and trial completion 8 weeks later. Outcomes from this feasibility study will inform a larger, fully powered clinical trial should the treatment show trends for potential effectiveness.

Trial registration: Australian New Zealand Clinical Trials Registry, ACTRN12617000053325 (http://www.ANZCTR.org.au/ACTRN12617000053325.aspx).

Keywords: Acupuncture, Endometriosis, Pelvic pain, EEG, CPM, Inflammation, Protocol

* Correspondence: M.armour@westernsydney.edu.au
1NICM, Western Sydney University, Campbelltown Campus, Sydney, Australia
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Chronic pelvic pain (CPP) is pain in the pelvis of greater than 6-month duration that is severe enough to cause functional disability or require medical intervention [1]. Worldwide prevalence rates range between 5.7 and 26.6% [2]. Endometriosis is the presence of endometrial tissue outside the uterine cavity and is the most common cause of CPP [3] with 24 to 40% of women with CPP diagnosed with endometriosis [4, 5]. Endometriosis-related CPP includes a variety of pain symptoms including dysmenorrhea (period pain), dyspareunia (pain during sexual intercourse), dyschezia (pain on bowel motions) and dysuria (pain on urination). In addition to pelvic visceral or muscle pain [4], endometriosis reduces quality of life and increases absenteeism at work or school [6]. A recent cohort study of Australian women aged 34–39 years had a prevalence of confirmed endometriosis of 3.7% [7]. However, a 2005 cross-sectional survey of 1983 menstrual-aged Australian women found that 21.5% of women had experienced non-menstrual pelvic pain and 14.1% had experienced dyspareunia over the past 12 months [8]. This suggests that the prevalence of endometriosis may be significantly greater than 3.7%.

Chronic pain has been identified as a top five health concern by Australian women [9] and is a National Women’s Health priority [10]. Endometriosis impacts women’s health and wellbeing, including social activities [6], mental and emotional health [11], work and finances [6] and sexual relationships [12], and has been shown to reduce physical quality of life similar to that of cancer patients [6]. The economic cost burden of endometriosis is substantial [6, 13]. A European multi-country study found that, on average, the total economic cost burden was €9579 (2010 prices) comprising both health care costs (approx. 33%) and productivity losses (approx. 66%) due to absence from work as a result of pelvic pain [6]. Further, the productivity loss associated has been estimated to be similar to or higher than certain chronic disease burdens, including diabetes mellitus, Crohn’s disease and rheumatoid arthritis which are commonly recognised as priority disease areas across health sectors [14].

Current treatments such as non-steroidal anti-inflammatories, oral contraceptive pills and hormonal treatments have limited effectiveness [13], and the side effect profile is bothersome, with discontinuation rates of 25–50% [15]. Surgical interventions are costly and invasive, and recurrence rates for pain are high, with 50% of women having pain recurrence at 5 years post-surgery [3, 13]. Early evidence from two recent studies comparing verum (true) acupuncture to sham acupuncture have shown promise in reducing endometriosis-related CPP using a short course (10–16 sessions) of treatment [16, 17].

Acupuncture may reduce endometriosis-related CPP through multiple mechanisms including the potential to reduce prostaglandin expression [18], reduce nerve growth factor [19], increase endogenous opioid release [20] and reduce mechanical allodynia [19]. However, the effects of acupuncture on three key areas that are altered in women with chronic pelvic pain are still unclear: increased inflammatory markers, changes in neuronal functional connectivity, and altered endogenous pain modulation.

Interleukin-6 (IL-6) is a cytokine and inflammatory marker implicated in the pathogenesis of endometriosis [21]. Serum IL-6 levels raised in women with endometriosis [22, 23] are positively correlated with disease stage [24] and change in response to symptom severity during treatment [25]. Acupuncture has been shown to reduce IL-6 levels [18, 19], and one small study examined the effect of Japanese acupuncture on IL-6 in women with endometriosis, but due to recruitment issues, the study was too underpowered to detect any differences [17]; therefore, acupuncture’s effect on IL-6 in endometriosis remains unclear.

Neuroimaging research shows a correlation between endometriosis-related CPP, depression and anxiety and increased connectivity between the anterior insula and medial prefrontal cortex [26]. A recent systematic review shows acupuncture has the ability to regulate pain-related functional connectivity [27], but there has been no investigation of acupuncture’s effect on functional connectivity in women with CPP. Electroencephalography (EEG) is a simple, low-cost method that can be used to investigate functional connectivity [28]. Dysfunctional endogenous pain inhibition is also commonly found in chronic pain conditions [29]; however, its presence in endometriosis-related CPP has not yet been demonstrated.

Conditioned pain modulation (CPM) is a technique to investigate individual differences in pain inhibition in women with CPP and can be used to investigate changes in endogenous pain inhibition after acupuncture treatment. Investigation of these physiological biomarkers that could underpin the efficacy of acupuncture in conjunction with clinical outcomes has the potential to fill a significant gap in our knowledge of acupuncture’s potential mechanism(s) of action and is a key area for acupuncture research [30].

The aim of this study is to assess the feasibility and acceptability of acupuncture and to investigate any changes in physiological biomarkers when using acupuncture to treat endometriosis-related CPP. Primary feasibility objectives will be evaluated in terms of recruitment (interest to participate in the trial, identification of appropriate recruitment strategies, the appropriateness of eligibility criteria), retention (compliance with treatment attendance and dropout rates), safety (adverse event rates) and appropriateness of the outcome measures (compliance with data
collection). Secondary patient-centred outcomes to be evaluated include a change in 0–10 daily pelvic pain ratings, the Endometriosis Health Profile 30 (EHP-30) and changes in conditioned pain modulation, resting and task-related EEG activity and inflammatory markers.

Methods/design
This is an 8-week, two armed, parallel group assessor-blind, randomised controlled feasibility study.

Ethics approval for this study was granted in December 2016 by the Western Sydney University Human Research Ethics committee (H11984). The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN1261700053325) on January 11, 2017. The study protocol (version 3, 6/2/17) (see Additional file 1) has been designed in accordance with the SPIRIT guidelines [31] (see Additional file 2), Good Clinical Practice guidelines (1996) and the STRICTA guidelines for reporting of acupuncture trials [32]. Any changes to the trial protocol will be communicated to all investigators, reflected in changes to the trial registry and will be first approved via the ethics committee.

Recruitment, setting and informed consent
Recruitment will be primarily via Endometriosis Australia, a not-for-profit charity. Trial information and invitations to participate will be published on their website (http://www.endometriosisaustralia.org) as well as via their Facebook page and Twitter feed. A link to a screening page (http://nicm.edu.au/research/clinical_trials/endometriosis) will be provided by the recruiting organisation. Women will fill in a screening questionnaire, and their contact details will be collected. A researcher will contact potential participants, explain the study in detail and ensure the participant information sheet has been read and understood. Women who agree to participate will fill in a screening questionnaire, and their contact details will be collected. A researcher will contact potential participants, explain the study in detail and ensure the participant information sheet has been read and understood. Women who agree to participate will fill in a 4-week baseline pelvic pain diary that records the severity of both menstrual and non-cyclical pelvic pain. Four weeks is considered adequate to obtain baseline pain measures in women with endometriosis [33]. Potential participants will also need to provide a copy of the laparoscopic findings confirming a diagnosis of endometriosis. Upon returning these to the research team, eligibility will be confirmed and written consent obtained, including consent to take and store blood samples. The trial intervention will be conducted in Sydney, Australia, at both NICM at Western Sydney University’s Campbelltown campus, and several private acupuncture practices in the greater Sydney area.

Eligibility criteria
Women will be eligible to participate in the trial if they:

- Are aged 18–45 years
- Have a laparoscopic diagnosis of endometriosis in the last 5 years as per current clinical guidelines [33–35]
- Are having regular menstruation (every 3–5 weeks)
- Have menstrual or non-menstrual pelvic pain rated ≥4/10 on a numeric rating scale
- Report at least one of the following: dysmenorrhea, dyspareunia, dyschezia or dysuria

Women will not be eligible to participate if they have had endometriosis surgery or started the oral or injectable contraceptive pill, GnRH-a or danazol, within the last 6 months. Women who do not meet the initial eligibility criteria will be logged. Women who decline to participate after initial contact will also be logged, with a reason for declining (if given).

For the EEG component of the study, women will be screened for suitability for EEG measurement. EEG exclusion criteria are as follows:

- Diagnosed psychiatric disorders including dissociative disorder, obsessive-compulsive disorder, personality disorder, schizophrenia and bipolar disorder
- History of drug and alcohol dependence or substance-related disorders
- History of seizures
- Head trauma with loss of consciousness
- Left-handedness

Participants who are not eligible for EEG measurement will still be accepted into the trial and will complete all other outcome measures.

Randomization, allocation concealment and blinding
Practitioners and participants will not be blinded. Research assistants and others performing data collection, data entry and analysis will be blind to group allocation. Participants will be asked not to mention any details of their treatment or their group allocation to the assessor(s). If blinding is compromised, another assessor will be contacted and will complete the data collection. A computerised, internet-based central randomisation service (sealedenvelope.com) will be used to provide randomisation and allocation concealment. Women will be randomised in a 1:1 ratio between acupuncture and usual care. Once known, the primary investigator will communicate the group allocation to the participant.

Treatment schedule
**Acupuncture + usual care**

Women in this group will receive 16 acupuncture treatments over 8 weeks, twice weekly with a minimum of
48 h between treatments, delivered by registered Chinese medicine practitioners in private clinics or by a registered Chinese medical practitioner at the clinic room at NICM. All study acupuncturists will have a minimum of 5 years experience, with a minimum of a bachelor’s level qualification in acupuncture, and will hold current Chinese Medicine practitioner registration with the Australian Health Practitioner Regulation Agency (AHPRA). Practitioners will be located in central and western Sydney areas. MA is also an acupuncturist and will train the practitioners in the trial protocol as well as deliver treatments to those women who find treatment at Campbelltown campus geographically convenient.

Acupuncture treatment will be delivered using a standardised fixed set of acupuncture points, based on those used in a previous pilot clinical trial using a traditional Chinese medicine (TCM) framework to treat endometriosis [16]. The set acupuncture points that will be delivered every session are SP6, SP8, SP10, ST29, ST36, CV3, CV4 and LR3. All participants will receive the same acupuncture points, with no individualisation based on TCM diagnosis. Table 1 outlines the rationale and anatomical location for these points based on the common presenting symptoms of endometriosis.

Acupuncture points will be needled bilaterally, DeQi obtained and needles retained for 25–30 min. DeQi (the arrival of Qi) is the sensation generated by the insertion and/or manipulation of an acupuncture needle in an acupuncture point and is often described as a dullness, heaviness or distending sensation [36]. Point location and needling depth will be as specified in A Manual of Acupuncture [37]. Single-use, stainless steel needles of varying gauge (0.20 × 30.00 mm or 0.25 × 40.00 mm), dependent on body shape, will be used. All reporting of the acupuncture intervention in the final manuscript will conform to the STRICTA guidelines [32]. All participants in the acupuncture group will also continue with their usual care as currently prescribed or advised by either their general practitioner or gynaecological specialist, the specifics of which are the same as the usual care only group.

**Usual care only**
All participants will continue with their usual care as currently prescribed or advised by either their general practitioner or gynaecological specialist. Usual care will be based on specific medical advice that has been given to the participant but commonly involves the oral contraceptive pill or non-steroidal anti-inflammatory or analgesic medication. The use of usual care alone will allow the natural progression and fluctuations in CPP to be isolated from the effect of acupuncture.

**Prohibited and permitted concomitant treatment**
No other TCM co-interventions (moxibustion, cupping or herbal medicine) will be permitted during the trial. Participants will continue with all prescribed medication

| Acupuncture point | Relevant indication(s) for endometriosis [37] | Location |
|-------------------|-----------------------------------------------|----------|
| Sanyinjiao (SP6)  | Irregular menstruation, uterine bleeding, dysmenorrhea, abdominal masses in women | 3 cun* directly above the tip of the medial malleolus |
| Diji (SP8)        | Irregular menstruation, dysmenorrhea, abdominal masses in women | On the medial aspect of the lower leg, 3 cun below SP9, on the line connecting the tip of the medial malleolus and SP9 |
| Xuehai (SP10)     | Irregular menstruation, dysmenorrhea, abdominal masses in women | When the knee is flexed, on the medial aspect of the thigh, the point is 2 cun above the mediusuperior border of the patella, on the bulge of the medial portion of m. quadriceps femoris. |
| Zhongji (CV3)     | Masses below the umbilicus, severe pain below the umbilicus, abdominal masses, irregular menstruation, painful urination, infertility | On the anterior median line of the lower abdomen, 4 cun below the umbilicus |
| Guanyuan (CV4)    | Fullness of the lower abdomen, back pain and twisting pain below the umbilicus that radiates to the genitals, painful urination, infertility | On the anterior midline, 3 cun below the umbilicus |
| Gulai (ST29)      | Irregular menstruation, uterine masses, pain in the vagina, infertility | 2 cun lateral to the anterior midline, level with CV 3 |
| Zusanli (ST36)    | Distension and pain of the abdomen | On the anterior aspect of the lower leg, 3 cun below ST 35, one finger breadth (middle finger) from the anterior crest of the tibia |
| Taichong (LR3)    | Epigastric or abdominal pain, periumbilical pain, pain of the genitals, irregular menstruation, painful urinary dysfunction, difficult defecation | On the dorsum of the foot, in the depression distal to the junction of the first and second metatarsal bones |

*Acupuncture point nomenclature as per World Health Organisation guidelines for meridian alphabetic codes

*A cun is a measurement used in locating acupoints, and corresponds to the distance between the two medial ends of the creases of the interphalangeal joints, when the patient’s middle finger is flexed
and can use analgesics as needed for pain relief. All analgesic usage is noted in the daily pain diary.

Assessment schedule
There is a 4-week screening period prior to trial entry, followed by an 8-week treatment intervention. Participants in both groups will need to attend baseline and end of trial measurements at NICM on Western Sydney University’s Campbelltown campus. Table 2 outlines the assessments during the total 12-week period.

Outcome measures
Patient-reported outcomes, neurophysiological measures and blood samples will be collected at the various time points outlined in Table 2. Baseline demographic data on age, ethnicity, menstrual history, smoking, current medication and revised American Society of Reproductive Medicine (rASRM) classification [38] of endometriosis will be collected by the primary investigator (MA) prior to the baseline visit to NICM. Baseline 0–10 numeric rating scale (NRS) pain scores for both non-cyclical and menstrual pain will be collected prior to trial entry during the screening period. The EXPECT questionnaire will be used to determine expectancy and belief in acupuncture at baseline [39]. Financial and personal impact of endometriosis will be collected via the ENDOCOST questionnaire at baseline [40]. The traditional Chinese medicine differential diagnosis thought to underlie participants’ symptoms will be recorded by the treating acupuncturist. All pain scores and questionnaires are self-reported and all analyses will be performed blind to group allocation.

Primary feasibility outcomes
The primary outcome for this trial is the feasibility and acceptability of the recruitment methods, intervention and outcome measures. Feasibility outcomes include the following:

a) Recruitment rate (interest to participate in the trial, identification of appropriate recruitment strategies and the appropriateness of eligibility criteria)

Recruitment rate will be calculated as the number of women who are eligible for randomisation out of those who express interest in the trial.

b) Retention (compliance with treatment attendance and dropout rates)

Retention will be calculated as the number of women who complete all 16 acupuncture sessions

Table 2 Timeline of treatment assessments and interventions

| Period       | Screening                  | Treatment |
|--------------|----------------------------|-----------|
| Week         | PB                         | B 1 2 3 4 5 6 7 8 |
| Daily 0–10 pain diary | X | X X X X X X X X |
| Presence of endometriosis comorbidities | X | X X X X X X X X |
| Rescue analgesic medication usage | X | X X X X X X X X |
| Proof of laparoscopic diagnosis | X |
| Eligibility screening | X |
| Informed consent signed | X |
| Randomisation | X |
| Demographic characteristics | X |
| ENDOCOST Survey | X⁵ |
| EHP-30 | X⁵ | X |
| Internal Health Locus of Control measurement | X⁵ |
| EXPECT questionnaire | X⁵ |
| CPM | X | X⁵ |
| IL-6 levels | X | X⁵ |
| EEG | X | X⁵ |
| Acupuncture treatment | X X X X X X X X X X |
| Safety assessment | X X X X X X X X |
| CGI-I | X |
| Treatment satisfaction/feasibility measures | X |

PB after screening questionnaire received and eligibility confirmed, B Baseline visit to NICM lab, EHP-30 Endometriosis Health Profile 30-item questionnaire, EEG electroencephalography, CPM conditioned pain modulation test, IL-6 interleukin 6, CGI-I Clinical Global Impression scale-Improvement

⁵Forms will be completed after randomisation and will be returned during the baseline visit

⁶Visit to NICM lab at end of week 8
Secondary patient-centred outcomes

a) The pelvic pain outcome measures are daily 0–10 NRS for non-cyclical pelvic pain and a separate daily 0–10 NRS used for menstrual pain during the period itself via a daily pain diary. Pain scores are to be recorded in the evening, with one number capturing the overall pain for the day. The 11-point numeric rating scale is recommended as being suitable to score both dysmenorrhea and pelvic pain in women with endometriosis [33]. Scores for menstrual (pain that occurs when menstrual bleeding is present) and non-menstrual pelvic pain will be considered separately, as summing them may obscure the true extent of potential improvement [33]. During the menstrual period, the single daily pain score will reflect menstrual-related pain, while outside of menses will reflect non-cyclical pain. Pain scores will be recorded daily for 4 weeks prior to trial entry to provide a suitable baseline and daily for 8 weeks during the trial period itself. Daily non-menstrual pain scores will be converted into a single non-menstrual pain scores at three time points, baseline, month 1 and month 2. This will be achieved by taking the mean of the daily pain scores for the previous 4 weeks, excluding any days where menstruation was noted. Menstrual pain scores will be calculated by the mean of the daily pain scores for each menstrual period at each of the three time points.

b) The Endometriosis Health Profile 30 (EHP-30) is an endometriosis-specific patient-reported outcome that examines health-related quality of life (HRQoL) in women with endometriosis. The EHP-30 is a user-friendly, valid and reliable condition-specific tool to assess HRQoL [41] and contains questions on physical and emotional functioning as recommended by the IMMPACT guidelines [42]. The EHP-30 will be measured at baseline and at trial completion.

c) The Clinical Global Impression scale (CGI). A modified version of the global improvement question [43] will be used at trial exit to determine the minimal clinically important difference in NRS rated pain scores in women with endometriosis, by using comparing changes in patients’ self-assessment scores with changes in NRS scores to derive a non-inferiority margin. Similar techniques have been used for VAS pain scores in women with endometriosis [43].

d) Prevalence and severity of comorbidities. The daily prevalence and severity (mild, moderate or severe) of common endometriosis comorbidities including dyspareunia, dysuria and dyschezia.

e) Analgesic medication usage. The use of any rescue analgesic medication (e.g. paracetamol or ibuprofen) will be logged using the daily pain diary.

f) Internal health locus of control (iHLoC). Internal health locus of control is a measure of how much control individuals feel that they can exert over their own health, as opposed to their health being strongly influenced by either luck and/or chance or powerful external entities, such as God or a doctor [44]. Internal health locus of control will be measured at baseline and trial completion.

g) Traditional Chinese medicine (TCM) acupuncture differential diagnosis. TCM texts emphasise the importance of treating both the root (the underlying cause) and the branch (symptomatic treatment) via accurate differential diagnosis [45]. The individualisation of treatment based on differential diagnosis is considered to be fundamental to acupuncture practice [46]. Collection of the TCM differential diagnosis given by the treating acupuncturist will provide data on any possible correlation between diagnosis at trial entry and other physiological biomarkers.

Physiological biomarker collection and processing

a) Human electroencephalography (EEG) is a non-invasive recording technique that captures ongoing electrical brain activity via strategically placed scalp electrodes. The excellent temporal resolution of EEG makes it the ideal methodological approach for investigating the neuronal mechanisms associated with intervention-related changes. EEG recordings will be undertaken between day 4 and 11 of the menstrual cycle for women not using oral contraceptives, or any day of the menstrual cycle where women are taking an active hormonal contraceptive treatment, to minimise hormonally related fluctuations that can influence recordings [26, 47]. Participants will have a 64-channel sintered Ag/AgCl electrode cap fitted. Electro-oculogram (EOG) will also be recorded using sintered Ag/AgCl electrodes placed 2 cm above and
below the left eye for vertical movements and on the outer canthus of each eye for horizontal movements. Data will be acquired DC–70 Hz, digitised at 1000 Hz and amplified with a gain of 2816 using a Neuroscan Synamps2 digital signal-processing system and Neuroscan 4.5.1 Acquire software. A conducting gel will be inserted into all electrodes, and their impedances will be kept below 10 kΩ. Resting-state EEG activity (2 min each of eyes open, eyes closed and eyes open) will be recorded for 6 min; this will be used to quantify resting-state functional connectivity.

A simple visual discrimination task (modified version of the AX-Continuous Performance Test (AX-CPT)) will then be presented to assess whether the intervention has affected the activated brain state. The modified AX-CPT allows the testing of sustained attention, processing speed and executive function (inhibition, error detection). Deficits in context-induced error processing from this version of the AX-CPT correlate well with performance on the Stroop task. Stimuli consisting of the letters A, X, B and Y will be presented in a quasi-random sequence. Participants are instructed to respond to the letter X (target) when it is proceeded by the letter A (cue). Stimuli are presented for a duration of 250 ms, at a fixed inter-stimulus interval (ISI) of 1.2 s. The probability of correct AX pairings will be \( p = 0.7 \) so that participants have a pre-potent response. Incorrect AY (cued nontarget; context-induced errors), BX (uncued target; context-free errors) and BY (uncued nontarget; random responding) pairings will each be presented at a probability of \( p = 0.1 \). A total of 500 stimuli will be presented (AX = 350, AY = 50, BX = 50 and BY = 50). Display and stimulus markers will be controlled by a separate stimulus computer using Compumedics Stim2 (4.0.09302005) software.

Participants will be required to respond to correctly cued targets (AX) as quickly and as accurately as possible via a button press with the dominant hand using the Stim System Switch Response Pad (P/N 1141). Unrestricted temporal principal components analysis will be applied to quantify event-related potential (ERP) component amplitudes.

b) Conditioned pain modulation (CPM). CPM is a well-established, reliable and safe measure of pain processing that is thought to indicate the function of descending pain control systems. This is examined as a change in the pain perceived in one body region (test stimulation) as a result of pain induced in another body region (conditioned stimulation). We will use pressure pain threshold (PPT) measurement as the test stimulation and cold pain (3 °C ice bath) as the conditioned stimulation. Three PPTs (test stimulation) will be measured before the application of cold pain (conditioned stimulation). Cold pain will be applied by placing the participants’ dominant hand (to the wrist) in a circulating water bath at a cold temperature (maximum 3 °C) for 2 min. The water temperature will be checked prior to each test to ensure that it is in accordance with the protocol. Three PPT measurements will be repeated 30 s after applying the conditioned stimulation. Participants will be asked to rate their pain during conditioned stimulation on a numeric rating scale (0–100) at 0 s, at 30 s and at the end of the trial. Pain scores will be maintained between 50 and 80/100 during testing.

c) Interleukin-6 (IL-6) levels. A blood sample will be collected from participants by a trained phlebotomist during the first testing session (after informed consent and screening) and again at trial conclusion 8 weeks later. A trained phlebotomist will collect ~10 ml of blood (one vacutainer) from the median cubital vein (cubital fossa anterior to the elbow). Samples will be transported to the NICM pharmacology laboratory by a member of the research team for processing as per the Australian Standard “Packaging for surface transport of biological material that may cause disease in humans, animal and plants—AS4834”. All samples will be de-identified and stored in the NICM of −80 °C freezer following centrifugation. Samples will be thawed and batch tested at the conclusion of the trial. Serum samples will be tested in duplicate for IL-6 levels using Quantikine high sensitivity solid phase ELISA immunoassays (R&D Systems Human IL-6 Quantikine HS ELISA, In Vitro Technologies, Victoria, Australia).

Criteria for success

This feasibility trial will be deemed a success and lead to the development of a proposal for a fully powered randomised controlled trial if:

- The acupuncture intervention is deemed to be safe and acceptable based on combination of participant satisfaction at the end of the trial, the type and rate of adverse events, and adherence rates (at least 75% of women completing at least 12 of the 16 treatment sessions).
- At least 30 participants are recruited during the 9-month trial recruitment period.
- At least 30% of those expressing interest in the trial are eligible to complete to the baseline measurements.
- At least 67% of participants complete the follow-up session at the NICM lab at the completion of the trial.
Modifications may be made to the protocol for the full study based on participant feedback and recruitment rates, including the addition of additional clinical/laboratory sites.

Sample size
This trial is not designed to establish efficacy but rather to assess feasibility. At least 30 women in total will be recruited for this study which we estimate will answer our feasibility questions on recruitment and retention rates based on a previous feasibility study of acupuncture in Australia women of a similar age that recruited 20 women and had a dropout rate of 15% [48]. A minimum of fifteen women will be allocated to each group in a 1:1 ratio, with a predicted dropout rate of 10–15%.

Statistical analysis
Baseline demographics will be reported using descriptive statistics. Primary feasibility outcome measures are descriptive statistics (measures of central tendency [e.g. mean], variability [e.g. standard deviation] and effect size [e.g. standardised mean difference and confidence intervals]) for recruitment rates, dropout rates, adverse event rates and acceptability data. An exploratory analysis of secondary patient-centred outcomes will also be undertaken. NRS levels for menstrual and non-menstrual pain will be analysed using repeated measures at baseline, month 1 and month 2 via a longitudinal linear mixed model analysis of variance with time and group as fixed effects and subject as a random effect. Changes in IL-6 levels and CPM scores will be assessed using paired t tests. Categorical data such as expectation levels and comorbidities will be analysed using Fisher’s exact tests. Missing data for the pain diaries will not be imputed as the linear mixed model analysis of variance does not require manual imputation. Missing data for other outcomes will be imputed using last observation carried forward (LOCF). Functional connectivity analyses will be applied to post-processed resting-state EEG data using eLORETA (exact low resolution brain electromagnetic tomography) [49–51]. Task-state post-processed EEG data (ERPs from the AX-CPT) will be submitted to an unrestricted principal components analysis with Varimax rotation to quantify ERP component (factor) amplitudes.

Quality assurance
Quality assurance measures on needleling technique will be carried out on practitioners during the study period by using an independent acupuncturist to check point selection and location at least once for each practitioner. Regular calibration and testing for CPM and EEG equipment will occur both prior to and during the data-recording period. The EEG laboratory has a SOP that all research assistants must adhere to when collecting data. The investigator GZS will oversee this process.

Safety monitoring
At each treatment session, the treating acupuncturist will ask the participants if they have had any adverse events or reactions after the last treatment. Any adverse events or reactions that are thought to be causally associated with the intervention will be recorded in the practitioner’s log book and reported to the PI. Any adverse events reported to the PI will be discussed with the other investigators to determine clinical significance. All adverse events reported during the duration of the trial will be recorded under adverse events as part of the case report form.

Discussion
Acupuncture is a low-risk treatment [52] that shows promise in targeting some of the physiological mechanisms underlying the pathogenesis of endometriosis, and preliminary clinical trials have shown clinically significant analgesia. Currently, there are no data on the minimal clinically important difference in pain when using the numeric rating scale in women with CPP. Understanding the minimal clinically important difference in pain is crucial for determining an appropriately powered clinical trial. In addition, the recruitment methods, safety and the acceptability of a twice weekly acupuncture intervention and the appropriateness of the three biomarkers as outcome measures are vital feasibility components that need to be understood prior to embarking on a fully powered randomised controlled trial. A fixed point selection was chosen as this has shown effectiveness in a previous clinical trial on TCM acupuncture for endometriosis [16]. This reduces the effect of treatment variation between practitioners but at the expense of ecological validity; however, as this is a feasibility study, this is not a significant issue. Previous trials for endometriosis have shown promising results after 10 treatments delivered twice per week [16] and after 16 treatments delivered twice per week [17]. In this study, we decided to treat twice weekly for 8 weeks (16 treatments) as this gives a greater cumulative dose of acupuncture delivered [53].

This study will be the first to investigate the possible mechanisms of acupuncture using two physiological techniques with this clinical population. No previous study has examined the role of the endogenous pain modulation system in women with endometriosis or used EEG to examine changes in functional connectivity after acupuncture treatment in women with chronic pelvic pain. This study addresses current methodological challenges and recommendations in acupuncture research [30], allowing a preliminary investigation into the correlation between clinical outcomes and changes in
biomarkers and any relationship between biomarkers at entry and presenting acupuncture TCM differential diagnosis. An improved understanding of the possible mechanisms of action of acupuncture in altering pain processing and inflammation will guide future trial design to strengthen the evidence base for acupuncture.

**Trial status**

Recruitment commenced February 2017.

**Additional files**

- **Additional file 1:** Treatment of endometriosis related chronic pelvic pain: study protocol v3. (DOCX 74 kb)
- **Additional file 2:** SPIRIT 2013 Checklist: recommended items to address in a clinical trial protocol and related documents. (DOC 120 kb)

**Abbreviations**

AHPRA: Australian Health Practitioner Regulation Agency; AUD: Australian dollars; CPP: Conditioned pain modulation; CPM: Chronic pelvic pain; EEG: Electroencephalogram; EHP-30: Endometriosis Health Profile 30; IL-6: Interleukin-6; NRS: Numeric rating scale; SAR: Society for Acupuncture Research; SOP: Standard operating procedure; TCM: Traditional Chinese medicine

**Acknowledgements**

A/Prof Jason Abbot provided significant input on factors related to endometriosis and study design. Adele E. Cave will provide support on EEG and CPM data collection and analysis as a research assistant. Endometriosis Australia will provide significant assistance in trial recruitment.

**Funding**

Funding for this project was provided by an Early Career Researcher Development Grant supplied by Western Sydney University. SMS and GZS receive salary support from the National Health and Medical Research Council (NHMRC) of Australia (SMS: APP1105040, GZS: APP1102532).

**Availability of data and materials**

Not applicable.

**Authors’ contributions**

MA, CS, SS, GZS, XZ, KL and JS all contributed to the conceptualisation and design of the study. MA and CS took the lead on drafting the study protocol, and all authors provided critical feedback. JS provided clinical guidance on endometriosis treatments; KL provided statistical advice on cost of illness; GZS provided expert advice on EEG; SMS provided expert advice on CPM. XZ provided expert advice on acupuncture specific details. All authors approved the final manuscript.

**Competing interests**

MA is the director of an acupuncture clinic in New Zealand and has recently been engaged in integrative medicine clinical practice. MA, CS, GZS and XZ are part of NICM. As a medical research institute, NICM receives research grants and donations from foundations, universities, government agencies, individuals and industry. Sponsors and donors provide untied funding for work to advance the vision and mission of the Institute. The project that is the subject of this article was not undertaken as part of a contractual relationship with any organisation other than the funding declared in the “Acknowledgements” section. It should also be noted that NICM conducts clinical trials relevant to this topic area, for which further details can be provided on request. KL, JS and SS declare no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Ethics approval for this study was granted in December 2016 by the Western Sydney University Human Research Ethics committee (H18404). Written consent for participation and for taking and storing of blood samples will be obtained prior to randomisation.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1NICM, Western Sydney University, Campbelltown Campus, Sydney, Australia.
2Brain Rehabilitation and Neuroplasticity unit, Western Sydney University, Campbelltown Campus, Sydney, Australia. Centre for Health Research, Campbelltown Campus, Western Sydney University, Campbelltown Campus, Sydney, Australia. 3Department of Obstetrics and Gynaecology, SWSLHD Camden and Campbelltown Hospitals, Sydney, Australia.

Received: 13 March 2017 Accepted: 8 June 2017

**Published online:** 06 July 2017

**References**

1. Howard F, Perry P, Carter J, El-Minawi A. Pelvic pain: diagnosis and management. Philadelphia: Lippincott Williams and Wilkins; 2000.
2. Ahangari A. Prevalence of chronic pelvic pain among women: an updated review. Pain Physician. 2014;17(2):E141–7.
3. Hickey M, Ballard K, Farquhar C. Endometriosis. BMJ. 2014;348:g1752. doi:10.1136/Bmj.g1752.
4. Whitaker LH, Reid J, Choa A, McFee S, Serreytny M, Wilson J, et al. An exploratory study into objective and reported characteristics of neuropathic pain in women with chronic pelvic pain. PLoS One. 2016;11(4):e0151950. doi:10.1371/journal.pone.0151950.
5. Mowers EL, Lim CS, Skinner B, Mahnert N, Kamdar N, Morgan DM, et al. Prevalence of endometriosis during abdominal or laparoscopic hysterectomy for chronic pelvic pain. Obstet Gynecol. 2016;127(6):1045–53. doi:10.1097/AOG.0000000000001422.
6. Nnoaham KE, Hummelshoj L, Webster P, d’Hooghe T, de Cicco NF, de Cicco NC, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96(2):366–73. doi:10.1016/j.fertnstert.2011.05.090. e8.
7. Fisher C, Adams J, Hickman L, Sibbritt D. The use of complementary and alternative medicine by 7427 Australian women with celiac perimenstrual pain and discomfort: a cross-sectional study. BMC Complement Altern Med. 2016;16:129. doi:10.1186/s12906-016-1119-8.
8. Pitts MK, Ferris JA, Smith AM, Shelley JM, Richters J. Prevalence and correlates of three types of pelvic pain in a nationally representative sample of Australian women. Med J Aust. 2008;189(9):438–43.
9. Joan Hailes for Women’s Health Network. Women’s Health Survey 2016: understanding health information needs and health behaviours of women in Australia. 2016.
10. Australian Government Department of Health and Aging. National Women’s Health Policy. 2010.
11. Sepulcra R, do Amaral VF. Depressive symptoms, anxiety, and quality of life in women with pelvic endometriosis. Eur J Obstet Gynecol Reprod Biol. 2009;142(1):53–6. doi:10.1016/j.ejogrb.2008.09.003.
12. Pluchino N, Wenger JM, Petignat P, Tal R, Bolmont M, Taylor HS et al. Sexual function in endometriosis patients and their partners: effect of the disease and consequences of treatment. Hum Reprod Update. 2016. doi:10.1093/humupd/dmw031.
13. Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;3:CD009590. doi:10.1002/14651858.CD009590.pub2.
14. Zondervan KT, Yudkin PL, Vessey MP, Dawes MG, Barlow DH, Kennedy SH. Prevalence and incidence of chronic pelvic pain in primary care: evidence from a national general practice database. Br J Obstet Gynaecol. 1999;106(1):1149–55.
15. Sinal N, Cleary SD, Younes N, Ballweg ML, Stratton P. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime experience. Fertil Steril. 2007;87(6):1277–86. doi:10.1016/j.fertnstert.2006.11.051.
16. Rubi-Klein K, Kucera-Listuz E, Nissel H, Bijak M, Stockenhuber D, Fink M, et al. Is acupuncture in addition to conventional medicine effective as pain treatment for endometriosis? A randomised controlled cross-over trial. Eur J Obstet Gynecol Reprod Biol. 2010;153(1):90–3. doi:10.1016/j.ejogrb.2010.06.023.
17. Wayne PM, Kerr CE, Schnyer RN, Legedza AT, Savetsky-German J, Shields MH, et al. Japanese-style acupuncture for endometriosis-related pelvic pain in adolescents and young women: results of a randomized sham-controlled trial. J Pediatr Adolesc Gynecol. 2008;21(4):247–57. doi:10.1016/j.jpag.2007.07.008.

18. McDonald JL, Cripps AW, Smith PK. Mediators, receptors, and signalling pathways in the anti-inflammatory and antihyperalgesic effects of acupuncture. Evid Based Complement Alternat Med. 2012;2015:975632. doi:10.1155/2015/975632.

19. McDonald JL, Cripps AW, Smith PK, Smith CA, Xue CC, Gollanu B. The anti-inflammatory effects of acupuncture and their relevance to allergic rhinitis: a narrative review and proposed model. Evid Based Complement Alternat Med. 2013;2013:591796. doi:10.1155/2013/591796.

20. Mayor D. An exploratory review of the electroacupuncture literature: clinical applications and endorphin mechanisms. Acupunct Med. 2013;31(4):409–15. doi:10.1136/acupmed-2013-010324.

21. Lundeberg T, Lund I. Is there a role for acupuncture in endometriosis pain, or ‘endometrialgia’? Acupunct Med. 2008;26(2):194–110.

22. Martinez S, Gamido N, Copenera JL, Pardo D, Desco J, Garcia-Velasco JA, et al. Serum interleukin-6 levels are elevated in women with minimal-mild endometriosis. Hum Reprod. 2007;22(3):838–42. doi:10.1093/humrep/del419.

23. Bedaiwy MA, Falcone T, Sharma RK, Goldberg JM, Attaran M, Nelson DR, et al. Prediction of endometriosis with serum and peritoneal fluid markers: a prospective controlled trial. Hum Reprod. 2002;17(2):426–31.

24. Mosbah A, Nabié Y, Khabaza E. Interleukin-6, intracellular adhesion molecule-1, and glycodelin A levels in serum and peritoneal fluid as biomarkers for endometriosis. Int J Gynaecol Obstet. 2016;134(3):247–51. doi:10.1016/j.ijgino.2016.01.018.

25. Iwabe T, Harada T, Sakamoto Y, Iba Y, Horie S, Mitsunari M, et al. Gonadotropin-releasing hormone agonist treatment reduced serum interleukin-6 concentrations in patients with ovarian endometriomas. Fertil Steril. 2003;80(2):300–4.

26. As-Sanie S, Kim J, Schmidt-Wilcke T, Sunden CG, Clauw DJ, Napadow V, et al. Functional connectivity is associated with altered brain chemistry in women with endometriosis-associated chronic pelvic pain. J Pain. 2016;17:117–131. doi:10.1016/j.jpain.2015.09.008.

27. Villarello Santiago M, Timulty S, Maczink A, Mani R. Does acupuncture alter pain-related functional connectivity of the central nervous system? A systematic review. J Acupunct Meridian Stud. 2016;9(4):167–77. doi:10.1155/2016/341568.

28. Sockeel S, Schwarz D, Peleggi-Nissac M, Benali H. Large-scale functional networks identified from resting-state EEG using spatial ICA. PLoS One. 2016;11(1), e0146845. doi:10.1371/journal.pone.0146845.

29. Tracey I, Mantyh PW. The cerebral signature for pain perception and its modulation. Neuron. 2007;55(3):377–91. doi:10.1016/j.neuron.2007.05.038.

30. Langevin HM, Wayne PM, Macpherson H, Schnyer R, Milley RM, Napadow V, et al. Paradoxes in acupuncture research: strategies for moving forward. Evid Based Complement Alternat Med. 2011;2011:180805. doi:10.1057/s41598-016-0306-3.

31. Chan AW, Textlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krbic K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Based Complement Alternat Med. 2011;2011:180805. doi:10.1155/2011/180805.

32. Khong SY, Lam A, Luscombe G. Is the 30-item Endometriosis Health Profile (EHP-30) suitable as a self-report health status instrument for clinical trials? Fertil Steril. 2010;94(5):1928–32. doi:10.1016/j.fertnstert.2010.01.047.

33. Dworkin RH, Turk DC, Wyvis KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–21. doi:10.1016/j.jpain.2007.09.005.

34. Worrall CA, Wallston BS, DeVellis R. Development of the multidimensional health locus of control (MHLC) scales. Health Educ Monogr. 1978;62:160–70.

35. Kaptchuk TJ. The web that has no weaver. 2nd, illustrated, revised ed. McGraw-Hill Professional: Chicago, Ill; 2000.

36. Ryan JD. Practice styles of beginner practitioners. J Altern Complement Med. 2005;11(3):477–82.

37. Brotzner CP, Klimesch W, Doppelmayr M, Zauner A, Kerschbaum HH. Resting state alpha frequency is associated with menstrual cycle phase, estradiol and use of oral contraceptives. Brain Res. 2014;1577:36–44. doi:10.1016/j.braintor.2014.06.034.

38. Smith CA, Pirotta M, Kilbreath S. A feasibility study to examine the role of acupuncture to reduce symptoms of lymphoedema after breast cancer: a randomised controlled trial. Acupunct Med. 2014;32(5):387–93. doi:10.1177/10557895.2014.010593.

39. Paasch-Marquard RD, Lehmann D, Koulkou M, Kochi K, Anderer P, Saletu B, et al. Assessing interactions in the brain with exact low-resolution electromagnetic tomography. Philos Trans A Math Phys Eng Sci. 2011;369(1952):3768–84. doi:10.1098/rsta.2011.0081.

40. Paasch-Marquard RD. Instantaneous and lagged measurements of linear and nonlinear dependence between groups of multivariate time series: frequency decomposition. arXiv preprint arXiv:2011.1453. 2007.

41. Paasch-Marquard RD, Biscay-Lirio RJ. Dynamic interactions in terms of senders, hubs, and receivers (SHR) using the singular value decomposition of time series: theory and brain connectivity applications. arXiv preprint arXiv:1009.0796. 2010.

42. Macpherson H, Scullion A, Thomas KJ, Walters S. Patient reports of adverse events associated with acupuncture treatment: a prospective national survey. Qual Saf Health Care. 2004;13(5):349–55. doi:10.1136/qhc.13.5.349.

43. Armour M, Smith CA. Treating primary dysmenorrhea with acupuncture: a narrative review of the relationship between acupuncture ‘dose’ and menstrual pain outcomes. Acupunct Med. 2016;34(6):416–24. doi:10.1136/acupmed-2016-011110.